How to Use The Clinic's Injectable Pen (Step-by-Step)
How to Use The Clinic's Injectable Pen (Step-by-Step)The Clinic's...
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα/β/γ), a nuclear receptor family central to mitochondrial biogenesis, oxidative metabolism and exercise-mimetic gene programs. In preclinical models, SLU-PP-332 has been investigated for its ability to enhance mitochondrial function, support fat oxidation and improve endurance and cardiometabolic phenotypes.
The SLU-PP-332 Peptide Pen is configured for The Clinic 2 mL / 200-click pen system, delivering precise 100 mcg-equivalent steps per 10 clicks in a convenient, subcutaneous research format. It is intended for laboratory and educational research use only.
Primary Functions
- Supports modelling of cellular energy and mitochondrial performance without focusing on muscle loss.
Mechanism of Action & Findings
SLU-PP-332 is a pan-agonist of ERRα, ERRβ and ERRγ. By activating these receptors, it:
- Engages an aerobic-exercise gene program in preclinical models.
- Upregulates pathways involved in mitochondrial biogenesis and oxidative metabolism.
- Enhances cellular respiration and ATP production in animal studies.
- Supports fat oxidation and cardiometabolic phenotypes in murine models.
As of November 2025, the evidence base for SLU-PP-332 is preclinical only. Published work has been conducted primarily in murine models; no human clinical trials have been completed.
Dosage Protocol — Pen System (Subcutaneous Research Context)
The SLU-PP-332 Peptide Pen uses The Clinic standardised pen system for subcutaneous research dosing. All example values below are expressed in mcg and click counts for clarity.
- Pen volume: 2 mL
- Total clicks per pen: 200 clicks
- SLU-PP-332 content per pen: 2 mg (2000 mcg)
- Conceptual dose unit: 10 clicks = 100 mcg
- Implied per-click amount: 10 mcg per click (200 clicks × 10 mcg = 2000 mcg)
- Route: Subcutaneous injection only (e.g. abdomen or thigh, per lab SOP).
Suggested Dosing – Intro & Standard Phases (SC Models)
| Phase | Dose per Event (mcg) | Clicks per Event | Frequency (Example) | Notes |
|---|---|---|---|---|
| Intro / Tolerance (Days 1–3) | 100 mcg | 10 clicks | 2 × daily (morning & evening) | Initial response and tolerance mapping. |
| Standard Phase (Days 4–28) | 200 mcg | 20 clicks | 2 × daily (morning & evening) | Mitochondrial and metabolic modelling in SC research. |
Pro tip (research context): Many labs conceptually start at 100 mcg (10 clicks) per event, then maintain twice-daily 100–200 mcg exposures for steady-state metabolic and mitochondrial modelling.
How Long the Pen May Last (Approximate)
| Pen Content | Dose per Event | Approx. Events per Pen |
|---|---|---|
| 2.0 mg (2000 mcg) | 100 mcg (10 clicks) | ~20 events |
| 2.0 mg (2000 mcg) | 200 mcg (20 clicks) | ~10 events |
Actual usage will vary based on protocol design, model requirements and any deviation from the example framework above.
Expected Outcomes
In preclinical and mechanistic contexts, SLU-PP-332 has been associated with:
- Mitochondrial optimisation: Upregulation of oxidative metabolism and improved respiration markers.
- Sustained energy signatures: Exercise-like gene expression and endurance benefits in mice.
- Fat-oxidation support: Enhanced fat metabolism without compromising lean mass in animal models.
- Metabolic wellness themes: Favourable cardiometabolic phenotypes in preclinical research.
- Longevity interest: ERR-linked pathways intersect with energy, mitochondrial quality and metabolic flexibility.
These findings are model- and protocol-dependent and must not be interpreted as guaranteed or therapeutic outcomes in any species.
Use Cases & Exclusions
Typical Use Cases
- Projects modelling enhanced energy and mitochondrial support.
- Bioenergetics and performance research focused on ERR signalling.
- Models targeting safe fat oxidation while preserving lean tissue in animals.
- Longevity and cellular-wellness concept studies.
Who Should NOT Use
- Anyone under 18.
- Pregnant or breastfeeding women.
- Individuals with serious metabolic or endocrine conditions unless under explicit specialist oversight.
- Any subject with known allergy or sensitivity to peptides or excipients.
Potential Side Effects & Adverse Signals (Class-Based)
- Mild injection-site irritation (redness, itching, tenderness).
- Headache or mild nausea in sensitive models.
- Temporary restlessness or slight jitteriness.
- Occasional digestive discomfort.
These are drawn from general peptide experience and early anecdotal reporting; specific SLU-PP-332 human safety data do not exist as human trials have not been completed.
Health & Legal Disclaimer: This product is supplied strictly for laboratory, educational and research purposes only. It is not intended to diagnose, treat, cure or prevent any disease and is not registered as a medicine or dietary supplement. Statements regarding this compound have not been evaluated by the FDA, SAHPRA, EMA or any other regulatory authority. All handling, storage, use and disposal must comply with local laws, institutional SOPs and ethics requirements. Not for human or veterinary therapeutic use, ingestion or unsupervised self-administration.
SLU-PP-332 Peptide 2 mg – ERR Agonist
- Brand: The Clinic
- Product Code: SLU-PP-01
- Reward Points: 32
- Availability: In Stock
Available Options
Our Product Range
Your Cart
Your shopping cart is empty!
Latest From The Clinic
- NAD, SS-31, MOTS-c, and GHK for Energy, Wellness, and Healthy Aging Support
- MOTS-c, Glutathione, SS-31, and CTI for Older Endurance Athletes: Recovery, Resilience, and Training Response
- SS-31: Direct Mitochondrial Support in the Energy, Recovery, and Longevity Stack
- Advanced Meal Support: Simple Daily Nutrition Support When Appetite Is Low
- Introducing Glutathione: Antioxidant Defence, Skin Support, and Recovery Under Load
- The Dermal Reset : A new standard in skin refinement — coming soon
